Now that the Ruthigen (RTGN) spinoff IPO from Oculus (OCLS) has officially been completed I see very strong upside potential in Ruthigen. Ruthigen's IPO pricing was on the low side, due most likely to investor concerns about Oculus' ability to raise the total amount needed for it. Now that they have pulled it off, however, at just a $30 million valuation (not including warrants) it looks very cheap next to several comps...
...The tight share structure in Ruthigen is an attractive scenario. This could help generate a momentum upswing in the stock on its own if there are not enough shares on the float to satisfy investor demand in the open market once it begins trading, as has been the case with several biotech IPOs recently. There are a total of 4.2 million common shares outstanding, with 2 million of these shares held by Oculus that have a one-year lock-up period. This leaves the 2.2 million shares on the float...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.